Increasing Efforts Toward Preventing and Treating Life-Threatening Animal Diseases Acting as Catalyst for Veterinary Anti-infective Market Growth: Fact.MR Report
According to a new industry report released by Fact.MR, the global veterinary anti-infective marketis estimated at US$ 5.03 billion in 2024 and is forecasted to reach US$ 7.47 billion by the end of 2034.
Anti-infectives are medications that help prevent the spread or transmission of diseases. Moreover, veterinary anti-infectives are healthcare products that prevent or treat the spread of infectious diseases between humans and animals.
Growing emphasis on the prevention and treatment of fatal animal diseases are key market indicators for veterinary antibiotics. The veterinary anti-infective market is expanding at a moderate pace due to several factors, including the rising prevalence of foodborne and zoonotic illnesses, the popularity of pets, and the expansion of animal healthcare research and development.
Increasing concerns about pet health and the rising incidence of bacterial infections, especially in dogs, along with an increase in pet adoption are expected to contribute to the steady demand growth for veterinary anti-infective solution.
The global veterinary anti-infective market is projected to expand at a CAGR of 4% from 2024 to 2034.
The market is forecasted to reach US$ 7.47 billion by the end of 2034.
The market in the United States is set to reach a value of US$ 1.17 billion in 2024.
Brazil is estimated to account for 48.8% share of the Latin America market in 2024.
Revenue from the sales of veterinary anti-infectives in Chile is poised to reach US$ 183 million in 2024.
The market in Latin America is forecasted to expand at a CAGR of 4.4% from 2024 to 2034.
“Rise in foodborne infections, often originating from animals, is posing a threat to human health. This is a significant driver boosting demand for veterinary anti-infective medications,” says a Fact.MR analyst.
Leading Players Driving Innovation in the Veterinary Anti-Infective Market
Neogen Corporation; Phibro Animal Health Corporation; Sanofi (Merial Animal Health); Vetoquinol S.A.; Virbac S.A.; Zoetis, Inc.; Boehringer Ingelheim GmbH; Ceva Santé Animale; Indian Immunologicals Limited; Intas Pharmaceuticals Limited; Norbrook Laboratories Limited; Ashish Life Science Private; Zydus Animal Health Limited.
Increasing Government Efforts Promoting Veterinary Health Services in Hospitals and Clinics
Growth of the market for veterinary anti-infectives is driven by stricter regulations enacted to prevent animal diseases and increased awareness of veterinary healthcare. Government initiatives to encourage veterinary services in hospitals and clinics are driving market growth.
Rising demand for premium meat in the United States means that diseases are effectively avoided in cattle and treated when they do occur. With consumers growing more health conscious, it is imperative to ensure the welfare of farm animals. To maintain animal health and food safety, veterinary anti-infectives are crucial.
The Antimicrobial Resistance Multi-Stakeholder Partnership Platform was initiated in November 2022 by the Food and Agriculture Organization of the United Nations (FAO), the United Nations Environment Programme (UNEP), the World Health Organization (WHO), and the World Organization for Animal Health (WOAH), or the Quadripartite. Aside from making sure that the impact of antimicrobial resistance is being tackled internationally, this project seeks to raise awareness about the threat posed by antimicrobial resistance (AMR) to individuals, animals, plants, ecosystems, and livelihoods.
The US-based drugs and vaccines for pets and cattle manufacturer Elanco Animal Health Incorporated launched Increxxa, the newly approved treatment for cattle respiratory disease, in February 2021.
Tulathromycin, the active ingredient in Increxxa, is administered to cattle to reach the area of infection within the lung rapidly. The rapid action and long half-life allow the cattle additional time to develop a strong immune response. The active ingredient of Increxxa, tulathromycin, reduces the damaging effects of bovine respiratory disease; this product is for veterinary use.
More Valuable Insights on Offer:
Fact.MR, in its new offering, presents an unbiased analysis of the veterinary anti-infective market for 2019 to 2023 and forecast statistics for 2024 to 2034.
The study divulges the veterinary anti-infective market based on species (livestock animals, companion animals), drug class (antimicrobial agents, antiviral agents, antifungal agents, antiparasitic agents), mode of administration (oral, parenteral, topical), and distribution channel (veterinary hospitals, veterinary clinics, pharmacies),across seven major regions of the world (North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia & Pacific, and MEA).
Check out More Related Studies Published by Fact.MR:
The global contraceptives market is expected to grow from US$ 33 billion in 2023 to US$ 62 billion by 2033, at a 6.5% CAGR.
The insulin delivery devices market is set to expand from US$ 16.8 billion in 2023 to US$ 33.1 billion by 2033, growing at a 7% CAGR.
The self-care medical devices market, valued at US$ 13 billion in 2020, is projected to reach US$ 20 billion by 2031 at a 6% CAGR, with blood pressure monitors growing at 8% and holter monitors at 5%.
The global nizatidine market is anticipated to rise from US$ 5.1 billion in 2021 to US$ 12.2 billion by 2031, expanding at a 9% CAGR.
The fluoroscopy equipment market, valued at US$ 1.9 billion in 2022, is expected to reach US$ 3.5 billion by 2031, growing at a 6% CAGR.
The phototherapy devices market is expected to grow at a 7% CAGR, exceeding US$ 1.5 billion by 2031, while LED-based devices will expand at a 6% CAGR from 2021 to 2031.
The kidney cancer diagnostics market is expected to grow at a 7% CAGR from 2022 to 2032, reaching a valuation of US$ 800 million in 2022.
The global breast cancer diagnostics market, valued at US$ 5,977 million in 2025, is forecasted to reach US$ 12,451 million by 2035, growing at a 6.9% CAGR.